PT - JOURNAL ARTICLE AU - Moore, Catherine AU - Davies, Louise AU - Rees, Rhiannydd AU - Gifford, Laura AU - Lewis, Heather AU - Plimmer, Amy AU - Barratt, Andrew AU - Pacchiarini, Nicole AU - Southgate, Joel AU - the COG-UK Consortium AU - Bull, Matthew J. AU - Watkins, Joanne AU - Corden, Sally AU - Connor, Thomas R. TI - Localised community circulation of SARS-CoV-2 viruses with an increased accumulation of single nucleotide polymorphisms that adversely affect the sensitivity of real-time reverse transcription assays targeting Nucleocapsid protein AID - 10.1101/2021.03.22.21254006 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.22.21254006 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254006.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254006.full AB - Currently the primary method for confirming acute SARS-CoV-2 infection is through the use of molecular assays that target highly conserved regions within the viral genome. Many, if not most of the diagnostic targets currently in use were produced early in the pandemic, using genomes sequenced and shared in early 2020. As viral diversity increases, mutations may arise in diagnostic target sites that have an impact on the performance of diagnostic tests. Here, we report on a local outbreak of SARS-CoV-2 which had gained an additional mutation at position 28890 of the nucleocapsid protein, on a background of pre-existing mutations at positions 28881, 28882, 28883 in one of the main circulating viral lineages in Wales at that time. The impact of this additional mutation had a statistically significant impact on the Ct value reported for the N gene target designed by the Chinese CDC and used in a number of commercial diagnostic products. Further investigation identified that, in viral genomes sequenced from Wales over the summer of 2020, the N gene had a higher rate of mutations in diagnostic target sites than other targets, with 115 issues identified affecting over 10% of all cases sequenced between February and the end of August 2020. In comparison an issue was identified for ORFab, the next most affected target, in less than 1.4% of cases over the same time period. This work emphasises the potential impact that mutations in diagnostic target sites can have on tracking local outbreaks, as well as demonstrating the value of genomics as a routine tool for identifying and explaining potential diagnostic primer issues as part of a laboratory quality management system. This work also indicates that with increasing genomic sequencing data availability, there is a need to re-evaluate the diagnostic targets that are in use for SARS-CoV-2 testing, to better target regions that are now demonstrated to be of lower variability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementT.R.C. acknowledges support from the MRC, which funded the computational resources used by the project (grant reference MR/L015080/1), as well as specific funding from Welsh Government, which provided funds for the sequencing and analysis Welsh samples used in this study, via Genomics Partnership Wales. Welsh sequencing has also been supported by the COVID-19 Genomics UK Consortium (COG-UK), as well as using genomics data that has partly been funded/generated as part of COG-UK. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. T.R.C. also acknowledges funding as part of the BBSRC Institute Strategic Programme Microbes in the Food Chain (BB/R012504/1) and its constituent projects (BBS/E/F/000PR10348 and BBS/E/F/000PR10352). J. Southgate was supported by the BBSRC -funded South West Biosciences Doctoral Training Partnership (training grant reference BB/M009122/1). AB is supported by a UKRI CDT as part of the AIMLAC CDT (grant code EP/S023992/1, project reference 2414958).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study presented encompasses surveillance data collected for and generated by the COVID-19 Genomics UK Consortium (COG-UK, https://www.cogconsortium.uk/). The COG-UK study and collection and use of the data was assessed and approved by the PHE Research Ethics and Governance Group on the 8th of April 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used is provided in the COG-UK bioproject PRJEB37886 Samples used in the analysis are included in supplementary table S1 https://www.ebi.ac.uk/ena/browser/view/PRJEB37886